News Release(2023)

December 12, 2023

KORSUVA® IV Injection Syringe for Dialysis 17.5μg, 25.0μg and 35.0μg to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis

December 1, 2023

Notice Concerning Status of Acquisition of the Company's Own Shares

November 17, 2023

Kissei Introduces Natural Language Processing System

November 7, 2023

Announcement concerning the Results of the Acquisition of Treasury Shares through ToSTNeT-3

November 6, 2023

Notice concerning the Purchase of Treasury Shares through ToSTNeT-3

November 1, 2023

Notice Concerning Status of Acquisition of the Company's Own Shares

October 27, 2023

Notice Concerning Revisions to Financial Results Forecast

October 23, 2023

Results of Japanese Phase III Clinical Study of KORSUVA® IV Injection for Pruritus in Patients undergoing Hemodialysis Published in NEJM Evidence

October 2, 2023

Notice Concerning Status of Acquisition of the Company's Own Shares

September 25, 2023

KORSUVA® IV Injection Syringe 17.5μg, 25.0μg and 35.0μg Granted Marketing Authorization Approval in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis

September 1, 2023

Notice Concerning Status of Acquisition of the Company's Own Shares

August 1, 2023

Notice Concerning Status of Acquisition of the Company's Own Shares

July 19, 2023

KISSEI Announces Withdrawal of Application for Marketing Approval for Rovatirelin (KPS-0373) for the Treatment of Spinocerebellar Degeneration in Japan

July 3, 2023

Kissei Introduces Iktos AI Drug Discovery System

July 3, 2023

Notice Concerning Status of Acquisition of the Company's Own Shares

June 1, 2023

Notice Concerning Status of Acquisition of the Company's Own Shares

May 8, 2023

Notice Regarding Purchase of Treasury Shares and Cancellation of Treasury Shares

April 21, 2023

Notice Concerning Revisions to Financial Results Forecast

April 6, 2023

Kissei Launches TAVALISSE® Tab. 100mg and 150mg, an Oral Spleen Tyrosine Kinase Inhibitor, in Japan for Chronic ITP